5 active not recruiting, 4 completed, 3 recruiting, 1 not yet recruiting. 9 Phase 2, 2 Phase 1, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 4, Completed 3, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Active not recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Chromophobe Renal Cell Carcinoma: new trials by email Literature Review of Chromophobe Renal Cell Carcinoma trials Research Report on Chromophobe Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer Proteomic profiling of urinary EVs, Blood sample collection - Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma | Not yet recruiting | Mayo Clinic | 300 | 2026-07-15 | 2026-02-27 | |
| A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit NN3201 - Gastrointestinal Stromal Tumors, Small-cell Lung Cancer | Phase 1 | Recruiting | Novelty Nobility, Inc. | 67 | 2025-02-03 | 2025-09-23 |
| Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma Cytokine Induced Memory-like Natural Killer (CIML NK) Cells, Interleukin-2 (IL-2) - Renal Carcinoma, Renal Cell Carcinoma | Early Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 5 | 2024-08-28 | 2026-10-23 |
| Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC Cabozantinib, Nivolumab, Ipilimumab - Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma | Phase 2 | Active not recruiting | Bradley A. McGregor, MD | 60 | 2020-11-05 | 2026-07-23 |
| Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 98 | 2020-07-29 | 2026-09-28 |
| An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy 13C-Glucose, 13C-Acetate, 13C-Lactate - Kidney Cancer, Renal Cell Carcinoma | Not applicable | Recruiting | University of Texas Southwestern Medical Center | 600 | 2019-09-30 | 2026-01-28 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-10-22 |
| ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) Cabozantinib - Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1 | Phase 2 | Completed | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 35 | 2019-04-11 | 2025-08-08 |
| A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma cabozantinib, nivolumab - Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2018-08-13 | 2026-09-21 |
| Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study Non-Interventional Study - Chromophobe Renal Cell Carcinoma, Clear Cell Papillary Renal Tumor | Completed | Mayo Clinic | 589 | 2018-06-27 | 2026-07-01 | |
| Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma Cabozantinib, Sunitinib Malate - Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 32 | 2018-05-15 | 2026-07-16 |
| Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) Nivolumab, Ipilimumab - Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1 | Phase 2 | Unknown | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 85 | 2017-10-19 | 2022-02-16 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Pazopanib Hydrochloride - Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma | Phase 2 | Completed | Mayo Clinic | 38 | 2013-05-16 | 2025-03-03 |
| Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer Bevacizumab, Sorafenib Tosylate, Pharmacological Study - Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 73 | 2005-05-01 | 2015-01-15 |
Carcinoma, Renal Cell (14) · Carcinoma, Transitional Cell (4) · Kidney Neoplasms (2) · Oncocytoma, renal (2) · Adenocarcinoma, Clear Cell (1) · Carcinoma, Adenoid Cystic (1) · Fumaric aciduria (1) · Gastrointestinal Stromal Tumors (1) · Hereditary leiomyomatosis and renal cell cancer (1) · Neuroendocrine Tumors (1) · Penile Neoplasms (1) · Piebaldism (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Urachal adenocarcinoma (1)
Adenocarcinoma (14) · Carcinoma (14) · Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Kidney Diseases (14) · Male Urogenital Diseases (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Neoplasms by Site (14) · Neoplasms, Glandular and Epithelial (14) · Urogenital Diseases (14) · Urologic Diseases (14) · Urogenital Neoplasms (13) · Urologic Neoplasms (13) · Kidney Neoplasms (12)
cabozantinib (6) · Nivolumab (4) · Ipilimumab (3) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Bevacizumab (1) · CTLA-4 Antigen (1) · Cell Count (1) · Interleukin-2 (1) · Sorafenib (1) · Sunitinib (1) · pazopanib (1) · radium Ra 223 dichloride (1)
Mayo Clinic (3) · National Cancer Institute (NCI) (3) · Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2) · Bradley A. McGregor, MD (1) · Dana-Farber Cancer Institute (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Novelty Nobility, Inc. (1) · University of Texas Southwestern Medical Center (1)
United States (12) · Australia (2) · Puerto Rico (1)
Andrea B Apolo (1) · Bradley McGregor, MD (1) · Brian Costello, M.D. (1) · Darren Feldman, MD (1) · David Pook, MBBS FRACPMD (1) · Fabrice Lucien-Matteoni, MD (1) · Jeffrey Sosman (1) · John B. Kisiel, MD (1) · Matthew T Campbell (1) · Rana R McKay (1) · Sunil Sharma, MD (1) · Vitaly Margulis, MD (1) · Wenxin Xu, MD (1)
PMID 33604999, PMID 35031545, PMID 35298296, PMID 42507969
U10CA180821 (2), F31CA239330 (1), P30CA068485 (1), P50CA196516 (1), R35CA220449 (1), U01CA099177 (1)